





# Nucleofection<sup>®</sup> Protocol for Ramos Cells – Transfection in Suspension

## Transfection Efficiency and Viability

This Optimized Protocol describes how to transfect Ramos cells on the 4D-Nucleofector<sup>®</sup> System and the 384-well Nucleofector<sup>®</sup> System. Transfection efficiencies of up to 41% can be achieved using pulse code CA-137 and 0.4 µg of pmaxGFP<sup>™</sup> Vector in 20 µL Nucleocuvette<sup>®</sup> Strips (analyzed 24h post Nucleofection<sup>®</sup> by flow cytometry). The cell viability of 69–71% was determined using the Vialight<sup>®</sup> Plus Assay and normalized to untransfected control samples. Similar transfection efficiencies can be achieved with 100 µL, 20 µL, single-well, 16-well, 96-well, and 384-well Nucleofection<sup>®</sup> Vessels as it is possible to transfer the experimental settings between systems. Visit the **Lonza Knowledge Center** for more information, including citations.

				
Cat. No	V4XC-3012/ V4XC-3024	V4XC-3032	V4SC-3096/ V4SC-3960	V5SC-3002*/ V5SC-3010*
Transfection volume	100 µL	20 µL	20 µL	20 µL
Size [reaction]	12/24	2 x 16	1 x 96/ 10 x 96	2 x 384/ 10 x 384
SG Cell Line Nucleofector <sup>®</sup> Solution	2 x 0.675 mL/ 2.25 mL	0.675 mL	2.25 mL/ 22.5 mL	22.5 mL/ 90 mL
Supplement 1	2 x 0.15 mL/ 0.5 mL	0.15 mL	0.5 mL/ 5 mL	5 mL/ 20 mL
pmaxGFP <sup>™</sup> Vector (1 µg/µL in 10 mM Tris pH 8.0)	50 µg	50 µg	50 µg	50 µg/ 150 µg
Single Nucleocuvette <sup>®</sup> Vessel (100 µL)	12/24	-	-	-
16-well Nucleocuvette <sup>®</sup> Strips (20 µL)	-	2	-	-
96-well Nucleocuvette <sup>®</sup> Plate (20 µL)	-	-	1/10	-
384-well Nucleocuvette <sup>®</sup> Plate (20 µL)*	-	-	-	2/10
To be used in conjunction with	4D-Nucleofector <sup>®</sup> Core and X Unit	4D-Nucleofector <sup>®</sup> Core and X Unit	4D-Nucleofector <sup>®</sup> Core and 96-well Unit	384-well Nucleofector <sup>®</sup> System

\* 384-well Nucleocuvette<sup>®</sup> plates are best handled with a liquid handling system. Contact **Scientific Support** for further information.

## Nucleofection® Handling

### Step 1

Harvest cells of interest.



### Step 2

Mix and combine. Nucleofector® Solution with supplement



Cells



Substrate



Transfer to a Lonza certified cuvette.



### Step 3

Select Nucleofector® Program. Insert cuvette. Press » Start «.



### Step 4

Rinse cuvette with culture medium.



### Step 5

Transfer to culture dish. Expression can be detected as soon as 3 – 8 hours post Nucleofection® Experiment.



[bioscience.lonza.com](http://bioscience.lonza.com)

## Recommended Kits: SG Cell Line Nucleofector® Kits

The SG Cell Line Kits are used with the modular 4D-Nucleofector® System or the high-throughput 384-well Nucleofector® System for efficient transfection of various mammalian cells including Ramos cells. The kits consist of two components that are not sold individually (conductive polymer cuvettes and a solution box) and are available in a single, 16-well, 96-well, and 384-well Nucleocuvette® Format. SG Cell Line Kit components are listed in the table above.

## Storage and Stability

Nucleofector® SG Cell Line Kits are shipped at room temperature. After receiving the kits, store Nucleofector® Solution, Supplement, and pmaxGFP™ Vector at 2–8°C and Nucleocuvette® Vessels at room temperature. For long-term storage, pmaxGFP™ Vector is ideally stored at -20°C. The expiration date is printed on the solution box.

Once the Nucleofector® Supplement is added to the Nucleofector® Solution, it is stable for three months at 4°C.

## Required Material

- Respective Nucleofector® System
- Supplemented SG Cell Line Nucleofector® Solution at room temperature

### Note

Please make sure to add Supplement 1 to the Nucleofector® Solution. The ratio of Nucleofector® Solution to Supplement is 4.5:1 (see Table 1). Prepare enough supplemented solution for the number of samples you want to transfect (see Table 3).

- Respective Nucleocuvette® Vessel
- If working with 20 µL Nucleocuvette® Strips or Plates: Use suitable pipette tips. Please make sure that your pipette tips reach the bottom of the Nucleocuvette® Wells without getting stuck

- If working with 384-well or 96-well Nucleocuvette® Plates: The 384-well Nucleofector® System and the 4D-Nucleofector® 96-Well Unit can be used either manually or automated on standard liquid handling instruments. For automated processing, consumables specific to your respective liquid handling system are required. For manual processing, we recommend using a multi-channel pipette
- Substrate of interest, highly purified, preferably by using endotoxin-free kits; for plasmid DNA A260/A280 ratio should be ~1.8
- Supplied pmaxGFP™ Vector, stock solution 1 µg/µL

### Note

When using pmaxGFP™ as a positive control, dilute the stock solution to an appropriate working concentration. Further details are provided in Table 3. The volume of substrate solution added to each sample should not exceed 10% of the total reaction volume (2 µL for 20 µL reactions; 10 µL for 100 µL reactions).

- Cell culture plates of your choice
- Culture medium: RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 100 µg/mL streptomycin, 100 U/mL penicillin, 2 mM Ultraglutamine I and 1 mM sodium pyruvate. Prewarm appropriate volume of culture medium to 37°C (see Table 2)
- Recovery medium (optional): Low calcium medium, e.g. RPMI
- Appropriate number of cells/sample (see Table 2)

## Pre Nucleofection®

### Cell Culture Recommendations

The viability and overall health of cells prior to transfection is well known to be important for optimal transfection results. Prior to transfection, cells should be at least 90% viable and have had adequate time to recover from passaging. We recommend the following culture conditions for Ramos cells:

- Replace media every 2 days
- Passage cells 3 times per week
- Cells should not be used for Nucleofection® Experiments after passage number 30
- Seed out 2.8–3.2 x 10<sup>5</sup> cells/mL

- Subculture cells 3 days before Nucleofection® Experiment
- Optimal cell density for Nucleofection® Experiments: 1.7–1.9 x 10<sup>6</sup> cells/mL. Higher cell densities may cause lower Nucleofection® Efficiencies

## Nucleofection®

Table 3 shows the recommended amount of substrate, cell number, and Nucleofection® Pulse Code for each sample.

- Please make sure that Supplement 1 has been added to the required amount of Nucleofector® SG Cell Line Solution (see Table 1)
- Start your respective Nucleofector® System and create or upload the experimental parameter file (see system manual for details)
- Select/Check for the appropriate Nucleofector® Pulse Code (see Table 3), we recommend pulse code CA-137 for the X Unit or corresponding programs for other units
- Prepare cell culture plates by filling an appropriate number of wells with the recommended volume of culture media (see Table 4) and pre-incubate (equilibrate) the plates at 37°C, 5% CO<sub>2</sub>
- Prewarm an aliquot of culture medium to 37°C (see Table 4)
- Make sure to dilute your substrate to the recommended working concentration (see Table 3)
- Take an aliquot of the cell suspension and count cells to determine the cell density
- Transfer the required amount of cells (see Table 3) to a new tube and pellet by centrifugation at 90xg for 10 minutes at room temperature. Gently remove all supernatant. Note that cell pellet may be looser than normal
- Resuspend the cell pellet carefully at room temperature in supplemented Nucleofector® SG Cell Line Solution (see Table 3). Gently pipette the cells to obtain homogeneous cell suspension
- Prepare master mixes by dividing cell suspension according to the number of substrates
- Add required amount of substrates to each aliquot (max. 10% of final sample volume)

## Note

When working with RNA, it is recommended to avoid longer incubation times as RNA is susceptible to degradation, although Nucleofector® Solutions are tested for absence of RNase activity

- Transfer master mixes into the respective Nucleocuvette® Vessels

## Note

It is important to work as quickly as possible as leaving cells in Nucleofector® Solution for extended periods of time may lead to reduced transfection efficiency and viability. Avoid air bubbles while pipetting. When working in a 96- or 384-well format it is recommended to either pre-dispense each cell suspension into a sterile round-bottom 96-well plate or to use reservoirs for multichannel pipettes.

- Gently tap the Nucleocuvette® Vessels on the benchtop to make sure the sample covers the bottom of the reaction vessel

## Note

When using the 384-well Nucleocuvette® Plate, instead of tapping you may briefly shake it with an appropriate microtiter-plate shaker to make sure the sample covers the bottom and sides of the wells without air bubbles.

- Place Nucleocuvette® Vessel with closed lid into the retainer of the Nucleofector® System. Check for proper orientation of the Nucleocuvette® Vessel
- Start the Nucleofection® Process by pressing “Start” on the display of your Nucleofector® System (for details, please refer to the respective system manual)
- After the Nucleofection® Process is completed, carefully remove the Nucleocuvette® Vessel from the retainer
- **Optional:** A recovery step can help to improve viability after the Nucleofection® Experiment. Add 100–300 µL pre-equilibrated recovery medium to the cuvette (instead of the standard culture media) and gently transfer it to a reaction tube. Place the cell suspension in an incubator for 5–10 minutes. Transfer the sample into the prepared culture dish and continue with section post Nucleofection®
- Resuspend cells with prewarmed medium (for recommended volumes see Table 4). Mix cells by gently pipetting up and down two to three times.

When working with the 100 µL Nucleocuvette® Vessels, use the supplied pipettes and avoid repeated aspiration of the sample

- Plate desired amount of cells in culture system of your choice (for recommended volumes, see Table 4)

## Post Nucleofection®

- Incubate the cells in humidified 5% CO<sub>2</sub> incubator at 37°C until analysis. Gene expression or downregulation, respectively, is often detected after just 4–8 hours.

## Selected References

- Erazo, Tatiana et al. “TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.” *Nature communications* (2022) vol. 13(1): 5676. doi:10.1038/s41467-022-33137-8
- Li, Dan et al. “Specific detection of interferon regulatory factor 5 (IRF5): A case of antibody inequality.” *Scientific reports* (2016) vol. 6: 31002. doi:10.1038/srep31002

**Table 1: Volumes required for a single reaction**

	100 µL	20 µL
<b>Volume of Nucleofector® Solution</b>	82 µL	16.4 µL
<b>Volume of Supplement 1</b>	18 µL	3.6 µL

**Table 2: Required amounts of cells and media for a Nucleofection® Reaction**

		16-well / 96-well	384-well
<b>Reaction volume</b>	100 µL	20 µL	20 µL
<b>Culture medium per sample post Nucleofection® (for transfer and culture)</b>	1.4 mL	230 µL	91 µL
<b>Cell number per Nucleofection® Sample</b>	2 x 10 <sup>6</sup> (Lower or higher cell numbers may influence transfection results)	4 x 10 <sup>5</sup> (Lower or higher cell numbers may influence transfection results)	4 x 10 <sup>5</sup> (Lower or higher cell numbers may influence transfection results)

**Table 3: Contents of one Nucleofection® Sample and recommended Pulse Code**

		Single Nucleocuvette® Vessel	16-well Nucleocuvette® Strips	96-well Nucleocuvette® Plate	384-well Nucleocuvette® Plate
<b>Reaction volume</b>		100 µL	20 µL	20 µL	20 µL
<b>Cells</b>		2 x 10 <sup>6</sup>	4 x 10 <sup>5</sup>	4 x 10 <sup>5</sup>	4 x 10 <sup>5</sup>
<b>Substrate*</b>	pmaxGFP™ Vector	2 µg	0.4 µg	0.4 µg	0.4 µg
<b>or</b>	plasmid DNA (in H <sub>2</sub> O or TE)	1–5 µg	0.2–1 µg	0.2–1 µg	0.2–1 µg
<b>or</b>	siRNA	30–300 nM siRNA (3–30 pmol/sample)	30–300 nM siRNA (0.6–6 pmol/sample)	30–300 nM siRNA (0.6–6 pmol/sample)	30–300 nM siRNA (0.6–6 pmol/sample)
<b>or</b>	mRNA	The amount of RNA must be optimized for each new mRNA. Too much RNA can have toxic effects, while too little RNA can lead to poor expression. RNA characteristics such as size or RNA features (e.g. poly-A tail, cap, or IRES) can have a significant impact on translation.			
<b>or</b>	RNPs	A dose-respond experiment should be performed to find the ideal RNP concentration after an appropriate RNP molar ratio has been established			
<b>SG Cell Line Solution</b>		100 µL	20 µL	20 µL	20 µL
<b>Pulse Code</b>		CA-137	CA-137	CA-137	CA-137-AA

\* Volume of the substrate should comprise a maximum of 10% of the total reaction volume

**Table 4: Culture volumes recommended for post Nucleofection® Steps and sample transfer**

		16-well / 96-well*	384-well**
<b>Reaction volume</b>	100 µL	20 µL	20 µL
<b>Culture medium pre-filled in 12-well culture plate</b>	1 mL	-	-
<b>Culture medium pre-filled in 96-well culture plate</b>	-	150 µL	-
<b>Culture medium pre-filled in 384-well culture plate</b>	-	-	51 µL
<b>Culture medium to be added to the sample post Nucleofection®</b>	400 µL	80 µL	40 µL
<b>Volume of sample transferred to culture plate</b>	complete sample (use supplied pipettes)	50 µL	9 µL

\* Maximum well volume: 200 µL. \*\* Maximum well volume: 60 µL

## Additional Information

For additional information and an up-to-date list of Nucleofector® References, please visit the Lonza Knowledge Center:

<https://knowledge.lonza.com>

## For more technical assistance, contact our Scientific Support Team:

### USA /Canada

Phone: 800 521 0390 (toll-free)  
Fax: 301 845 8338  
Email: [scientific.support@lonza.com](mailto:scientific.support@lonza.com)

### Europe and Rest of World

Phone: +49 221 99199 400  
Fax: +49 221 99199 499  
Email: [scientific.support.eu@lonza.com](mailto:scientific.support.eu@lonza.com)

Lonza Cologne GmbH – 50829 Cologne Germany

For research use only. Not for use in diagnostic procedures.  
The Nucleofector® Technology is covered by patent and/or patent pending rights owned by the Lonza Group Ltd or its affiliates. The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® System, Nucleofector® Solutions, and Nucleocuvette® Plates and Modules is covered by patent and/or patent pending rights owned by Lonza Cologne GmbH. Nucleofector, Nucleofection, Nucleocuvette and maxGFP are trademarks of Lonza Cologne GmbH in Germany and / or the U.S. and / or other countries.

All trademarks belong to Lonza, registered in USA, EU or CH or to third party owners and used only for informational purposes. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses. For more details: [www.lonza.com/legal](http://www.lonza.com/legal).